These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37563978)

  • 1. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis.
    Wu P; Huang C; Liao PF; Ruperto N; Zeng H
    Int J Rheum Dis; 2023 Nov; 26(11):2119-2121. PubMed ID: 37563978
    [No Abstract]   [Full Text] [Related]  

  • 2. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
    Bagri NK; King H; Ramanan AV
    Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
    Brunner HI; Foeldvari I; Alexeeva E; Ayaz NA; Calvo Penades I; Kasapcopur O; Chasnyk VG; Hufnagel M; Żuber Z; Schulert G; Ozen S; Rakhimyanova A; Ramanan A; Scott C; Sozeri B; Zholobova E; Martin R; Zhu X; Whelan S; Pricop L; Martini A; Lovell D; Ruperto N;
    Ann Rheum Dis; 2023 Jan; 82(1):154-160. PubMed ID: 35961761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Resolution of Erosive Psoriatic Juvenile Idiopathic Arthritis With Anti-Tumor Necrosis Factor Therapy.
    Felix MD; Ostrov BE
    J Clin Rheumatol; 2021 Dec; 27(8S):S688-S689. PubMed ID: 33136694
    [No Abstract]   [Full Text] [Related]  

  • 6. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Abbott proposes in Europe and the U.S.A. the approval of Humira (adalimumab) for therapy of juvenile idiopathic arthritis. Pediatric clinical trial shows very promising results in juvenile rheumatoid arthritis].
    Shandwick W; Bude S
    Kinderkrankenschwester; 2007 Aug; 26(8):335-6. PubMed ID: 17844688
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis.
    Immonen K; Kauppi M; Hakala M
    Scand J Rheumatol; 2011 May; 40(3):236-8. PubMed ID: 21231814
    [No Abstract]   [Full Text] [Related]  

  • 10. Three years of methotrexate and secukinumab: Outcomes of psoriatic arthritis in a real-life setting.
    Nicola S; Cassarino SG; Rolla G; Geronazzo G; Fornero M; Brussino L
    J Am Acad Dermatol; 2022 Jan; 86(1):241-243. PubMed ID: 33549655
    [No Abstract]   [Full Text] [Related]  

  • 11. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
    Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axial psoriatic arthritis: An update for dermatologists.
    Gottlieb AB; Merola JF
    J Am Acad Dermatol; 2021 Jan; 84(1):92-101. PubMed ID: 32747079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
    Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
    J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.
    Ho ACH; Wong SN; Leung LCK; Chan WKY; Chong PCY; Tse NKC; Yeung RHM; Kong SY; Lee KP
    Hong Kong Med J; 2020 Feb; 26(1):56-65. PubMed ID: 32077861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Shimizu M; Hamaguchi Y; Ishikawa S; Ueno K; Yachie A
    Mod Rheumatol; 2015; 25(6):972-3. PubMed ID: 25496406
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
    Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review.
    Barešić M; Smiljanić Tomičević L; Anić B; Mayer M
    Rheumatol Int; 2022 Feb; 42(2):365-370. PubMed ID: 35022831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis.
    Nelson MC; Manos CK
    J Investig Med High Impact Case Rep; 2023; 11():23247096231200403. PubMed ID: 37731263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriatic arthritis for the dermatologist.
    Tintle SJ; Gottlieb AB
    Dermatol Clin; 2015 Jan; 33(1):127-48. PubMed ID: 25412788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.